Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Journal of Gastroenterology
Published in: Clinical Journal of Gastroenterology 2/2024

11-12-2023 | Gastritis | Case Report

A case of nodular gastritis progression to autoimmune gastritis after 10 years of Helicobacter pylori eradication

Authors: Naoki Sumi, Ken Haruma, Kazuhiko Inoue, Nobumi Hisamoto, Katsuhiro Mabe, Takako Sasai, Toshio Ichiba, Maki Ayaki, Noriaki Manabe, Toshihiro Takao

Published in: Clinical Journal of Gastroenterology | Issue 2/2024

Login to get access

Abstract

A 61-year-old female patient underwent upper gastrointestinal endoscopy, which confirmed the presence of Helicobacter pylori (H. pylori)-positive nodular gastritis (NG). Routine upper gastrointestinal endoscopy after H. pylori eradication revealed atrophic changes of the corpus, having gradually progressed over the 10 years after successful eradication. Serological and biopsy specimen examination showed hypergastrinemia (1200 pg/mL), positive anti-parietal cell antibody (with a titer of more 160), and endocrine cell micronests after 11 years of H. pylori eradication. The patient was diagnosed with autoimmune gastritis (AIG) based on endoscopic, serological, and histological findings. This is the first report of AIG diagnosed in a patient with NG over a long period of time after H. pylori eradication.
Literature
1.
Strickland RG, Mackay IR. A reappraisal of the nature and significance of chronic atrophic gastritis. Am J Dig Dis. 1973;18:426–40.CrossRefPubMed
2.
Kawaguchi H, Haruma K, Komoto K, et al. Helicobacter pylori infection is the major risk factor for atrophic gastritis. Am J Gastroenterol. 1996;91:959–62.PubMed
3.
Kamada T, Maruyama Y, Monobe Y, et al. Endoscopic features and clinical importance of autoimmune gastritis. Dig Endosc. 2022;34:700–13.CrossRefPubMed
4.
Maruyama Y, Yoshii S, Kageoka M, et al. Endoscopic findings of autoimmune gastritis-chronic atrophic gastritis type A. I to Chou (Stomach Intestine). 2019;54:998–1009.
5.
Ihara T, Ihara N, Kushima R. Autoimmune gastritis with a long-term course of type B gastritis: a report of two cases. Intern Med. 2023;62:855–63.CrossRefPubMed
6.
Luzza F, Pensabene L, Imeneo M, et al. Antral nodularity identifies children infected with Helicobacter pylori with higher grades of gastric inflammation. Gastrointest Endosc. 2001;53:60–4.CrossRefPubMed
7.
Miyamoto M, Haruma K, Yoshihara M, et al. Nodular gastritis in adults is caused by Helicobacter pylori infection. Dig Dis Sci. 2003;48:968–75.CrossRefPubMed
8.
Sumi N, Haruma K, Kamada T, et al. Diagnosis of histological gastritis based on the Kyoto classification of gastritis in Japanese subjects—including evaluation of aging and sex difference of histological gastritis. Scand J Gastroenterol. 2022;57:260–5.CrossRefPubMed
9.
Terao S, Suzuki S, Yaita H, et al. Multicenter study of autoimmune gastritis in Japan: clinical and endoscopic characteristics. Dig Endosc. 2020;32:364–72.CrossRefPubMed
10.
Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969;1:87–97.CrossRef
11.
Rokkas T, Pistiolas D, Sechopoulos P, et al. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter. 2007;12(Suppl 2):32–8.CrossRefPubMed
12.
Murakami K, Kodama M, Nakagawa Y, et al. Long-term monitoring of gastric atrophy and intestinal metaplasia after Helicobacter pylori eradication. Clin J Gastroenterol. 2012;5:247–50.CrossRefPubMed
13.
Kong YJ, Yi HG, Dai JC, et al. Histological changes of gastric mucosa after Helicobacter pylori eradication: a systematic review and meta-analysis. World J Gastroenterol. 2014;20:5903–11.CrossRefPubMedPubMedCentral
14.
Stolte M, Meier E, Meining A. Cure of autoimmune gastritis by Helicobacter pylori eradication in a 21-year-old man. Z Gastroenterol. 1998;36:641–3.PubMed
15.
Müller H, Rappel S, Wündisch T, et al. Healing of active, non-atrophic autoimmune gastritis by H. pylori eradication. Digestion. 2001;64:30–9.CrossRefPubMed
16.
Kotera T, Nishimi Y, Kushima R, et al. Regression of autoimmune gastritis after eradication of Helicobacter pylori. Case Rep Gastroenterol. 2023;17:34–40.CrossRefPubMedPubMedCentral
17.
Sumi N, Haruma K, Urata N, et al. Autoimmune gastritis with rapid development of corporal atrophy found after H. pylori eradication therapy, report of a case. I to Chou (Stomach and Intestine). 2019;54:1053–7.
18.
Kotera T, Yoshioka U, Takemoto T, et al. Evolving autoimmune gastritis initially hidden by active Helicobacter pylori gastritis. Case Rep Gastroenterol. 2022;16:103–9.CrossRefPubMedPubMedCentral
19.
Ihara T, Ihara N, Kushima R, et al. Rapid progression of autoimmune gastritis after helicobacter pylori eradication therapy: a case report. Intern Med. 2023;62:1603–9.CrossRefPubMed
20.
21.
Okazaki K, Ohana M, Oshima C, et al. Interaction of Helicobacter pylori-induced follicular gastritis and autoimmune gastritis in BALB/c mice with post-thymectomy. J Gastroenterol. 2003;38:1131–7.CrossRefPubMed
22.
Hong SN, Jo S, Jang JH, et al. Clinical characteristics and the expression profiles of inflammatory cytokines/cytokine regulatory factors in asymptomatic patients with nodular gastritis. Dig Dis Sci. 2012;57:1486–95.CrossRefPubMed
Metadata
Title
A case of nodular gastritis progression to autoimmune gastritis after 10 years of Helicobacter pylori eradication
Authors
Naoki Sumi
Ken Haruma
Kazuhiko Inoue
Nobumi Hisamoto
Katsuhiro Mabe
Takako Sasai
Toshio Ichiba
Maki Ayaki
Noriaki Manabe
Toshihiro Takao
Publication date
11-12-2023
Publisher
Springer Nature Singapore
Published in
Clinical Journal of Gastroenterology / Issue 2/2024
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-023-01897-5

Other articles of this Issue 2/2024

Clinical Journal of Gastroenterology 2/2024 Go to the issue

Case Report

Two cases of pancreatic neuroendocrine tumors with ectopic ACTH syndrome during their disease course

Case Report

Patient with a novel syndrome with multiple benign hepatic lesions and extrahepatic neoplasms

Case Report

A rare incidence of a hepatic artery pseudoaneurysm following plastic biliary stent insertion

Case Report

A case of metachronous oligo-hepatic and peritoneal metastases of pancreatic cancer with a favorable outcome after conversion surgery combined with perioperative sequential chemotherapy

Case Report

A case of spindle and giant cell-type undifferentiated carcinoma of the extrahepatic bile duct

Case Report

A case of non-esophageal eosinophilic gastrointestinal disease diagnosed by mucosal incision-assisted biopsy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits